Skip to main content

Advertisement

Table 3 Attitudes regarding access to care and treatment recommendations

From: Oncologists’ and family physicians’ views on value for money of cancer and congestive heart failure care

  % stating strongly or somewhat agree P value
Oncologists Family physicians
Whether a cancer drug is included in the National List of Health Services influences my decision regarding which cancer treatment to recommend to my patients 77% 54% 0.005
Whether an intervention for congestive heart failure is included in the National List of Health Services influences my decision regarding which treatment to recommend to my patients   65%  
Whether a cancer drug is included in the National List of Health Services highly influences my patients’ access to treatment 92% 84% NS
Whether a treatment for congestive heart failure is included in the National List of Health Services highly influences my patients’ access to treatment   86%  
Every patient in Israel should have access to effective cancer treatments regardless of their cost 65% 55% NS
Every patient in Israel should have access to effective treatments for congestive heart failure regardless of their cost 73% 59% NS
Every effective cancer drug that is not included in the National List of Health Services should be included in the supplementary insurance offered by health plans 65% 76% NS
Every effective treatment for congestive heart failure that is not included in the National List of Health Services should be included in the supplementary insurance offered by health plans 65% 78% NS
Every effective cancer drug that is not included in the National List of Health Services should be included in commercial health insurance plans offered by private health insurance companies 75% 72% NS
Co-payment on cancer drugs is needed even if the drugs are included in the National List of Health Services 10% 10% NS
More research on comparative analysis of cancer drugs is needed 83% 85% NS
Data on the cost-effectiveness of new cancer drugs may have an impact on which treatment protocol to recommend to my patients 52% 64% NS
The notion that my patients will have to pay for a cancer drug “out of pocket” will influence my decision regarding which treatment protocol to recommend to my patients 79% 56% NS
How often do you discuss the costs of cancer drugs with your patients?    
 Always 6% 1% 0.007
 Frequently 17% 14%  
 Occasionally 50% 36%  
 Rarely 27% 34%  
 Never 0% 16%  
How often do you discuss the costs of treatments for congestive heart failure with your patients?    
 Always   2%  
 Frequently   16%  
 Occasionally   30%  
 Rarely   33%  
 Never   19%